Trending...
- Unveiling Puptqe: First-Ever Dog Bar Opening in Temecula Promenade This November
- Leonardo Defense Systems receives new investment and expands Team
- Supply Chain Industry Leaders: Embrace AI or Get Left Behind
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US
SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart failure, today announced the US Food and Drug Administration (FDA) has approved its application for an Expanded Access Program (EAP) for Revivent TC® System.
The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar, who have a suboptimal response to guideline-directed medical therapy. The procedure, referred to as Less Invasive Ventricular Enhancement (LIVE®) therapy, utilizes myocardial micro-anchor implants to reconstruct the dilated left ventricle to produce a more efficient chamber.
More on The Californer
The approval for an Expanded Access Program follows the successful completion of enrollment in the ALIVE (American Less Invasive Ventricular Enhancement) Trial, a prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System. Enrollment in the ALIVE Trial was completed in April 2022.
"The Expanded Access Program is a significant step for BioVentrix as we continue to build our real-world evidence to treat a dilated left ventricle, a maladaptive consequence of cardiac remodeling in ischemic and non-ischemic heart failure," said Jim Dillon, President and CEO of BioVentrix. "Heart failure patients with reduced ejection fraction (HFrEF) that are not responsive to standard-of-care therapies may now have access to LIVE Therapy, currently under investigation."
"While awaiting data analysis and US regulatory submission from the pivotal approval ALIVE Trial, enrollment in the Expanded Access Program will allow ongoing usage of the device and new insights into the predictors and magnitude of improvement of high-risk patients with heart failure undergoing the LIVE Procedure," said Gregg W. Stone, MD, Co-Principal Investigator of the ALIVE Trial, Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine and Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai, New York.
More on The Californer
"Expanded access that permits ongoing usage of this investigational device is critically important," said Jerry D. Estep, MD., Co-Principal Investigator for the ALIVE Trial and Chair of Cardiology, Cleveland Clinic Florida. "Patients with heart failure with high-risk features including significant shortness of breath despite medical management remain at high risk for disease progression and life-threatening events."
About BioVentrix
BioVentrix, Inc. is a privately held medical device company focused on the development of less invasive therapies to treat the failing left ventricle (LV), the most common cause of heart failure. BioVentrix technologies aim to improve cardiac function by directly addressing LV dilation. The Company markets the Revivent TC System in Europe and is preparing to submit the Premarket Approval (PMA) application to the FDA for the system later this year.
The BioVentrix, LIVE and Revivent TC trademarks are federally registered trademarks owned by BioVentrix. Any unauthorized use is expressly prohibited. Investigational Device.
Limited to Investigational Use Only In The United States.
SOURCE BioVentrix, Inc.
SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix®, Inc., a privately held medical device company focused on the development of less invasive therapies to directly treat the dilated left ventricle and reverse the left ventricular remodeling process of progressive heart failure, today announced the US Food and Drug Administration (FDA) has approved its application for an Expanded Access Program (EAP) for Revivent TC® System.
The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and extensive left ventricular scar, who have a suboptimal response to guideline-directed medical therapy. The procedure, referred to as Less Invasive Ventricular Enhancement (LIVE®) therapy, utilizes myocardial micro-anchor implants to reconstruct the dilated left ventricle to produce a more efficient chamber.
More on The Californer
- You're invited to Monogram International's booth (#265) at New York Toy Fair
- RBB Bancorp Announces Termination of Agreement to Acquire Gateway Bank, F.S.B.
- Yo Egg to Unveil Exclusive Plant-Based Quail-Sized Egg at the Vkind Experience
- The Law Offices of Frank R. Cruz Announces Investigation of GigaCloud Technology Inc. (GCT) on Behalf of Investors
- California Increases Minimum Wage, Protections for Fast-Food Workers
The approval for an Expanded Access Program follows the successful completion of enrollment in the ALIVE (American Less Invasive Ventricular Enhancement) Trial, a prospective, multi-center, dual-arm pivotal study of the BioVentrix Revivent TC System. Enrollment in the ALIVE Trial was completed in April 2022.
"The Expanded Access Program is a significant step for BioVentrix as we continue to build our real-world evidence to treat a dilated left ventricle, a maladaptive consequence of cardiac remodeling in ischemic and non-ischemic heart failure," said Jim Dillon, President and CEO of BioVentrix. "Heart failure patients with reduced ejection fraction (HFrEF) that are not responsive to standard-of-care therapies may now have access to LIVE Therapy, currently under investigation."
"While awaiting data analysis and US regulatory submission from the pivotal approval ALIVE Trial, enrollment in the Expanded Access Program will allow ongoing usage of the device and new insights into the predictors and magnitude of improvement of high-risk patients with heart failure undergoing the LIVE Procedure," said Gregg W. Stone, MD, Co-Principal Investigator of the ALIVE Trial, Director of Academic Affairs for the Mount Sinai Heart Health System and Professor of Medicine and Population Health Sciences and Policy at the Icahn School of Medicine at Mount Sinai, New York.
More on The Californer
- Do Grandparents Make Good Parents?
- RNA and DNA Endonuclease from Serratia marcescens
- Cardless Unveils Enhanced Simon Card with 5% Cash Back at Every Store At Simon Centers
- Dream Foundation Hosts The No Gala Gala to Raise Critical Funds
- Sparkling Logic Partners with Hitachi Solutions Create to expand Decision Management and Digital Decisioning in Japan
"Expanded access that permits ongoing usage of this investigational device is critically important," said Jerry D. Estep, MD., Co-Principal Investigator for the ALIVE Trial and Chair of Cardiology, Cleveland Clinic Florida. "Patients with heart failure with high-risk features including significant shortness of breath despite medical management remain at high risk for disease progression and life-threatening events."
About BioVentrix
BioVentrix, Inc. is a privately held medical device company focused on the development of less invasive therapies to treat the failing left ventricle (LV), the most common cause of heart failure. BioVentrix technologies aim to improve cardiac function by directly addressing LV dilation. The Company markets the Revivent TC System in Europe and is preparing to submit the Premarket Approval (PMA) application to the FDA for the system later this year.
The BioVentrix, LIVE and Revivent TC trademarks are federally registered trademarks owned by BioVentrix. Any unauthorized use is expressly prohibited. Investigational Device.
Limited to Investigational Use Only In The United States.
SOURCE BioVentrix, Inc.
Filed Under: Business
0 Comments
Latest on The Californer
- Phe - Pro - Arg - Chloromethylketone
- United Security Bancshares Declares Quarterly Cash Dividend
- Green Office Partner Ranks on the Inc. 5000 Annual List of the Fastest Growing Companies in America
- Office Calgary Inc, announces office expansion plans
- Halloween Reminders for Parents
- BYD Motors, Cox Automotive Announce Groundbreaking Service Partnership in U.S. Market
- PCV Murcor Employees and PCV|VRM Seeds of Hope Donates to Maui Strong Fund
- Cruise, University of Michigan Transportation Research Institute present groundbreaking study establishing a human driving safety benchmark
- Rubio's Coastal Grill Launches New & Improved Mobile App
- Southeast Ventura County YMCA Gala--November 4 At The Ronald Reagan Presidential Library
- PFW Recap: CHOCHENG Spring/Summer 2024 Les Parapluies De CHOCHENG
- The New Trace One Ushers in a New Era for CPG and Retail Product Innovation
- Design and development of a minimalistic fashion photography website
- Why PerfectionGeeks is the Best Dapp Development Company
- Adjust's New Growth Score Metric Reveals Worldwide User Acquisition Opportunities For Mobile App Marketers And Developers USA - English USA - English
- Zumigo Announces Record Business Growth as Industry Demand for its Mobile Identity Authentication Products Surges
- Jade Ann Byrne Unleashes Country Magic Raincheck my Cock-A-Doodle-Do
- Cloudflare and Meta Collaborate to Make Llama 2 Available Globally
- Long Beach Seeks Volunteers for 16th Annual Bike and Pedestrian Count
- Gryphon's Award-Winning Container Application Transforms Home Network Security Distribution